The 6th Meeting of the European Society of Oncological Urology (ESOU) will be held in Istanbul, Turkey, from 16 to 18 January 2009, with organisers presenting the latest updates on treatment strategies to onco-urology specialists.
With the fast-changing developments in onco-urological treatment strategies, the ESOU aims to provide urologists, gynaecologists, oncologists, scientists and researchers the opportunity to explore the various options that will enable cancer specialists to identify optimal treatment approaches.
“The ESOU is - and intends to remain - one of the most important platforms of scientific information exchange among experts as well as professionals interested in the field. It will continue to serve as a key opinion leader and promote the dissemination of high-quality uro-oncological scientific information, in order to increase the quality of medical service,” said ESOU Chairman Prof. Vincent Ravery (Paris, France).
The most common malignancies such as prostate cancer (PCa), renal cell carcinoma and bladder cancer were the focus of last year’s meeting in Berlin. Apart from these conditions, testis cancer will be another highlight of the forthcoming meeting in Istanbul.
Prof. Levent Türkeri (Istanbul, Turkey), ESOU board member and local organiser said: “On Friday, 16 January, an interesting pro-contra debate is organised entitled ‘Should hormones (adjuvant/neo-adjuvant) be dedicated to radiotherapy and abandoned in patients to be treated with surgery?’ Furthermore, the lecture by Prof. Theo de Reijke of the European Organisation on the Research and Treatment of Cancer-Genitourinary Group (Update on the recent data retrieved from EORTC GU group studies) deserves attention.”
The introduction of targeted therapies, which will be discussed during the sessions on renal cell carcinoma, meant a revolution in the field of oncology in general. These therapies appear to evolve into the mainstay of medical treatment of malignancies of the urogenital tract and are likely to convert the disease from a progressive and lethal one into a chronic, controllable process in many cases.
Notes:
Established in 2001, the ESOU, a full member of the EAU Section Office, organises two meetings every year, one of them during the EAU congress, with the first meeting held in January. Approximately 500 participants are expected in Istanbul. The 6th ESOU Meeting is also accredited within the EU-ACME programme by the European Board of Urology (EBU).
For more information, please visit http://www.uroweb.org.
Source:
Lindy Brouwer
European Association of Urology
Similar Posts:
- 6th ESOU Meeting: Updates In Onco-Urology
- “Mitochondrial Dysfunction In Neurological Diseases” 6th Meeting In “Emergence & Convergence” Series
- Clinical Outcome Following Prostatic Capsule- And Seminal-Sparing Cystectomy For Bladder Cancer In 25 Men
- The Von Hippel-Lindau Gene: Turning Discovery Into Therapy
- CHMP Recommends Granting Marketing Authorisation For FIRMAGON(R) (degarelix) For Treatment Of Prostate Cancer
The 6th Meeting of the European Society of Oncological Urology (ESOU) will be held in the Ceylan InterContinentall in Istanbul (TR), from 16 to 18 January 2009, with organisers presenting the latest updates on treatment strategies to onco-urology specialists. With the fast-changing developments in onco-urological treatment strategies, the ESOU aims to provide urologists, gynaecologists, oncologis
La Fondation Ipsen and Nature Publishing Group share the same desire to help new scientific knowledge emerge and facilitate the exchange of the most promising ideas from a variety of different research areas. In 2007, the two organisations came together to create a new series of scientific events - the Emergence & Convergence mini-symposia - one-day meetings highlighting some of the most dynamic
UroToday.com - In a recent article in the Scandinavian Journal of Urology and Nephrology, the authors evaluated the long-term outcomes of 25 men who underwent a prostate capsule- and seminal-sparing cystectomy. They hypothesized that this approach would improve continence and potency. Twenty-five male patients underwent cystectomy with preservation of the seminal vesicles, posterior prostate and
UroToday.com - Cancer remains a leading cause of morbidity and mortality in the United States. Efforts to reduce the pain and suffering due to cancer have met with some successes over the last several decades. Nevertheless, it has become increasingly apparent that further progress requires a more fundamental understanding of cancer’s underlying biology. The discovery and characterization of the v
Ferring Pharmaceuticals received notification that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMEA), has adopted a positive opinion and is recommending to grant a marketing authorization for FIRMAGON(R) (degarelix), a new GnRH receptor antagonist indicated for patients with advanced, hormone-dependent prostate cancer. In Phase III studies deg